CEL-SCI Corp Asset Resilience Ratio
CEL-SCI Corp asset resilience ratio. CEL-SCI Corp (CVM) has an Asset Resilience Ratio of 27.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of CEL-SCI Corp to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CEL-SCI Corp (1999–2025)
Asset resilience ratio of CEL-SCI Corp from 1999 to 2025. This chart shows how CEL-SCI Corp's Asset Resilience Ratio has changed over time. Read CEL-SCI Corp debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down CEL-SCI Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CEL-SCI Corp (CVM) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $6.28 Million | 27.42% |
| Short-term Investments | $7.09K | 0.03% |
| Total Liquid Assets | $6.28 Million | 27.45% |
Asset Resilience Insights
- Very High Liquidity: CEL-SCI Corp maintains exceptional liquid asset reserves at 27.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
CEL-SCI Corp Industry Peers by Asset Resilience Ratio
Compare CEL-SCI Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
CEL-SCI Corp Asset Resilience Ratio by Year (1999–2025)
CEL-SCI Corp asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for CEL-SCI Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 38.93% | $10.96 Million | $28.16 Million | +21.36pp |
| 2024-09-30 | 17.57% | $4.74 Million | $26.99 Million | +3.99pp |
| 2023-09-30 | 13.58% | $4.15 Million | $30.53 Million | -31.29pp |
| 2022-09-30 | 44.87% | $22.67 Million | $50.52 Million | -10.76pp |
| 2021-09-30 | 55.64% | $42.21 Million | $75.87 Million | +17.38pp |
| 2020-09-30 | 38.26% | $15.51 Million | $40.54 Million | +7.69pp |
| 2019-09-30 | 30.57% | $8.44 Million | $27.62 Million | -4.28pp |
| 2018-09-30 | 34.85% | $10.31 Million | $29.59 Million | +24.51pp |
| 2017-09-30 | 10.34% | $2.37 Million | $22.92 Million | -16.16pp |
| 2016-09-30 | 26.50% | $3.07 Million | $11.60 Million | -- |
| 2015-09-30 | 0.00% | $0.00 | $15.45 Million | -- |
| 2014-09-30 | 0.00% | $0.00 | $19.23 Million | -- |
| 2013-09-30 | 0.00% | $0.00 | $10.84 Million | -- |
| 2012-09-30 | 0.00% | $0.00 | $16.07 Million | -- |
| 2011-09-30 | 0.00% | $0.00 | $18.63 Million | -- |
| 2009-09-30 | 3.44% | $1.59 Million | $46.03 Million | +2.08pp |
| 2008-09-30 | 1.36% | $200.00K | $14.68 Million | -11.80pp |
| 2001-09-30 | 13.16% | $593.38K | $4.51 Million | -14.08pp |
| 2000-09-30 | 27.24% | $3.76 Million | $13.81 Million | -14.87pp |
| 1999-09-30 | 42.11% | $3.20 Million | $7.60 Million | -- |
About CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation S… Read more